Some previous studies have suggested that AMPK, SIRT‐1 and PGC‐1α activity can be inhibited by obesity and other metabolic disorders, which impairs lipid and glucose metabolism in skeletal muscle.26, 63, 64. Here, PPARGC1A is linked to metabolic disease.